Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base. [PDF]
Krah NM +6 more
europepmc +1 more source
Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]
Khalife-Hachem S +15 more
europepmc +1 more source
A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm on the Chest. [PDF]
Tokioka R, Saito-Sasaki N, Sawada Y.
europepmc +1 more source
Cutaneous Manifestation of a Rare Haematological Malignancy: A Case Report of the Presentation, Diagnosis, and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]
Hassan SL, Chatha DE.
europepmc +1 more source
Venetoclax and hypomethylating agents versus tagraxofusp in older patients with blastic plasmacytoid dendritic cell neoplasm. [PDF]
Lee BJ.
europepmc +1 more source
Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm. [PDF]
Galati D +5 more
europepmc +1 more source
Blastic plasmacytoid dendritic cell neoplasm: Two case reports. [PDF]
Ma YQ, Sun Z, Li YM, Xu H.
europepmc +1 more source
Related searches:
Blastic Plasmacytoid Dendritic Cell Neoplasm
Journal of the National Comprehensive Cancer Network, 2023Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with an aggressive clinical course and poor prognosis. BPDCN is most often characterized by its presentation with distinct cutaneous lesions. Bone marrow involvement, lymphadenopathy, splenomegaly, and/or cytopenias are also seen to varying degrees.
Akriti, Jain, Kendra, Sweet
openaire +3 more sources

